APA (7th ed.) Citation

Lang, N., Happle, R., & Hänßle, H. (2019). [Severe candidal balanoposthitis on concurrent treatment with secukinumab and the antidiabetic agent empagliflozin (sodium-glucose cotransporter 2 inhibitor-SGLT2-inhibitor)]: Reply. Journal der Deutschen Dermatologischen Gesellschaft, 17(4), . https://doi.org/10.1111/ddg.13816

Chicago Style (17th ed.) Citation

Lang, Nina, Rudolf Happle, and Holger Hänßle. "[Severe Candidal Balanoposthitis on Concurrent Treatment with Secukinumab and the Antidiabetic Agent Empagliflozin (sodium-glucose Cotransporter 2 Inhibitor-SGLT2-inhibitor)]: Reply." Journal Der Deutschen Dermatologischen Gesellschaft 17, no. 4 (2019). https://doi.org/10.1111/ddg.13816.

MLA (9th ed.) Citation

Lang, Nina, et al. "[Severe Candidal Balanoposthitis on Concurrent Treatment with Secukinumab and the Antidiabetic Agent Empagliflozin (sodium-glucose Cotransporter 2 Inhibitor-SGLT2-inhibitor)]: Reply." Journal Der Deutschen Dermatologischen Gesellschaft, vol. 17, no. 4, 2019, https://doi.org/10.1111/ddg.13816.